Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

Research output: Contribution to journalArticle

Abstract

Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been reported to induce immunomodulatory effects. We aimed to assess peripheral blood (PB) and bone marrow (BM) lymphocyte status at the diagnosis and during different TKI therapies and correlate it with treatment responses.

Details

Authors
  • Mohamed El Missiry
  • Shady Adnan Awad
  • Hanna L Rajala
  • Ahmed Al-Samadi
  • Marja Ekblom
  • Berit Markevän
  • Ingbritt Åstrand-Grundström
  • Maren Wold
  • Ellen Rabben Svedahl
  • Birgitte Ravn Juhl
  • Ole Weis Bjerrum
  • Inger Haulin
  • Kimmo Porkka
  • Ulla Olsson-Strömberg
  • Henrik Hjorth-Hansen
  • Satu Mustjoki
External organisations
  • Skåne University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology
Original languageEnglish
Pages (from-to)1041-1050
JournalJournal of Cancer Research and Clinical Oncology
Volume142
Issue number5
Early online date2016 Jan 8
Publication statusPublished - 2016
Publication categoryResearch
Peer-reviewedYes
Externally publishedYes